Johnson & Johnson Advances RYBREVANT for Head and Neck Cancer
RARITAN, N.J., July 30, 2026 Johnson & Johnson has secured U.S. Food and Drug Administration Priority Review for a...
Biologics License Application
Advertisement
Fresenius Kabi’s Vedolizumab Biosimilar Accepted for FDA and EMA Review
BAD HOMBURG, Germany, July 31, 2026 Fresenius Kabi, an operating company of Fresenius, announced that both the U.S. Food...
Ocugen Receives FDA RMAT Designation for OCU410 in Geographic Atrophy
MALVERN, Pa., July 29, 2026 Ocugen, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative...
Dyne Therapeutics Advances DMD Program with FDA Acceptance
WALTHAM, Mass., July 20, 2026 Dyne Therapeutics, Inc. (Nasdaq: DYN) announced that the U.S. Food and Drug Administration (FDA)...
Armata Advances AP-SA02 Toward Phase III Bacteremia Trial
LOS ANGELES, July 20, 2026 Armata Pharmaceuticals, Inc. has announced significant clinical, regulatory, manufacturing, and operational progress supporting the...
Advertisements
Persephoni Backs SelSym to Advance Trauma Bleeding Care
RESEARCH TRIANGLE PARK, N.C., July 15, 2026 Persephoni BioSciences has announced a strategic investment in SelSym Biotech, bringing the...
Genentech Wins FDA Priority Review for Gazyva in pMN
SOUTH SAN FRANCISCO, Calif., July 14, 2026 Genentech, a member of the Roche Group, has received U.S. Food and...
Mesoblast Completes Enrollment in Low Back Pain Trial
NEW YORK and MELBOURNE, July 13-14, 2026 Mesoblast Limited announced that it has achieved its target of treating at...
Hansoh Pharma Reports Positive Phase III Ris-Rez SCLC Results
SHANGHAI, China, July 10, 2026 Hansoh Pharmaceutical Group Co., Ltd. has announced that its Phase III ARTEMIS-008 clinical trial...
Avance Clinical Unveils Asia Growth Strategy at BIO Asia–Taiwan
TAIPEI, Taiwan | July 10, 2026 Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO), has announced its participation...
Advertisement
